**Supplementary Figure S1. Mean change from baseline in GHS/QoL (EORTC QLQ-C30) over time (PRO-evaluable population)**

CI confidence interval, *IPAT* ipatasertib, *PAC* paclitaxel, *PBO* placebo

Number of filled questionnaires																							
PBO + PAC	73	70	63	56	53	49	48	38	39	35	31	24	22	15	14	12	9	5	4	3	3	3	2	49
IPAT + PAC	127	121	113	108	101	94	89	78	70	65	58	43	38	27	25	21	14	12	10	7	7	5	2	85

Supplementary Figure S2. Time to confirmed ≥11-point deterioration in pain over time (ITT population)

IPAT ipatasertib, *NE* not evaluable, *PAC* paclitaxel, *PBO* placebo, *TTD* time to deterioration

Confirmed deterioration in pain	PBO + PAC (*N* = 76)	IPAT + PAC (*N* = 146)
Events, *n* (%)	23 (30)	56 (38)
Median TTD, months (95% CI)	NE (NE–NE)	NE (11.1–NE)
Stratified TTD hazard ratio (95% CI)	1.36 (0.83–2.22)	

Number at risk								
PBO + PAC	76	56	50	44	26	14	5	1
IPAT + PAC	146	104	87	67	45	24	10	3